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Despite treatments proven effective by sound study designs and robust end points, placebos remain integral to
elicit effective medical care. The authenticity of the placebo response has been questioned, but placebos likely
affect pain, functionality, symptoms, and quality of life. In cardiology, placebos influence disability, syncope,
heart failure, atrial fibrillation, angina, and survival. Placebos vary in strength and efficacy. Compliance to pla-
cebo affects outcomes. Nocebo responses can explain some adverse clinical outcomes. A doctor may be an un-
witting contributor to placebo and nocebo responses. Placebo and nocebo mechanisms, not well understood, are
likely multifaceted. Placebo and nocebo use is common in practice. A successful doctor-patient relationship can
foster a strong placebo response while mitigating any nocebo response. The beneficial effects of placebo, gener-
ally undervalued, hard to identify, often unrecognized, but frequently used, help define our profession. The role of
the doctor in healing, above the therapy delivered, is immeasurable but powerful. An effective placebo response
will lead to happy and healthy patients. Imagine instead the future of healthcare relegated to a series of guide-
lines, tests, algorithms, procedures, and drugs without the human touch. Healthcare, rendered by a faceless,
uncaring army of protocol aficionados, will miss an opportunity to deliver an effective placebo response. Wise
placebo use can benefit patients and strengthen the medical profession. (J Am Coll Cardiol 2007;49:415–21)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.036b
s
p
u
m
a
U
b
a
t
c
e
p
w
p
i
v
w
w
r
S
p
D
pplacebo is a sham, often a pill, but any intervention
urported to be therapeutic. Without direct physiologic or
harmacologic activity, a placebo somehow provides benefit
r apparent benefit. Nocebo is a sham, without direct
hysiologic or pharmacological activity, that causes harm or
pparent harm. This review critically examines placebo and
ocebo in cardiovascular medicine.
lacebo Effect: Is it Just a Sham?
ver the past 5 decades, the influential efforts of Beecher
1), Lasagna et al. (2), Shapiro (3–5), and others have had a
rofound impact on how placebo is portrayed, understood,
nd used. The seminal work of Beecher (1) continues to
hape medical, pharmaceutical, clinical, and behavioral re-
earch. With over 100,000 placebo citations in PubMed,
lacebo has set the standard for how clinical research is
onducted.
The widely accepted notion that placebo has any effect
as been challenged. Kienle and Kienle (6) argued that
lacebo effects can be explained by the natural history of a
isease, regression to the mean, concomitant treatments,
xperimental subordination, methodologic defects, observer
rom the University of Iowa Hospitals, Iowa City, Iowa.c
Manuscript received November 4, 2005; revised manuscript received September 5,
006, accepted September 7, 2006.ias (scaling bias), patient bias (conditioned answers, an-
wers of politeness). Kienle and Kienle (6) concluded that
lacebo effects are grossly overrated, illusory, and the prod-
ct of sloppy methodological thinking.
Subsequent analyses, comparing placebo with no treat-
ent, rather than to treatment, suggested that placebo has
negligible impact and its effects are overestimated (7–10).
pon re-analysis of these same data, placebo was found to
e effective for specific conditions (11). Methodologic and
nalytic issues remain unresolved. Poor study design, statis-
ical irregularities, patient and disease selection, and lack of
areful definition of what placebo is further obscures its
ffects and usefulness, yet, double and triple blinded
lacebo-controlled trials remain the best yardstick with
hich to measure scientific evidence.
A study designed to eliminate all real and apparent
lacebo effects requires that the investigator (if directly
nvolved) and patient not know anything about the inter-
ention or the expected outcome. An unbiased individual
ould administer therapy blinded to what is being given and
hy. The evaluator of the outcomes would not know who
eceived “real” therapy, what it was, or why it was given.
uch studies in cardiology are impractical, unethical, im-
ossible to complete, and of little clinical significance.
ouble-blind placebo-controlled trials, the best generally
ossible in cardiology, cannot eliminate a placebo effect
ompletely.
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Placebo and Nocebo January 30, 2007:415–21Placebo Effects
A placebo effect represents ben-
efit perceived by a patient or
identified by a practitioner aris-
ing solely from the appearance
that treatment is delivered. The
placebo effect does not require
that a pill be given. In 1 study,
6,000 psychiatric patients given
lacebo pills blindly were told that the pills would help
etermine the effectiveness of subsequent therapy (12). In
hort order, 51% improved, 12% deteriorated, 37% had no
esponse, and 57% had side effects. Placebo responses
redicted therapeutic responses, but none of 78 patient
haracteristics defined a responder (13).
The placebo effect may be temporary as it is for hyper-
ension (14), lasting weeks or months, or its effect can be
ongstanding as it can be with syncope (15). The diversity of
esponses and interventions makes temporal effects difficult
o characterize.
Placebo strength varies by the type of intervention. A
ose response exists (16). Blue (vs. pink) placebo pills are
edating. Yellow (vs. green) placebo pills are stimulating.
ed (vs. beige) placebos encourage a cardiac response.
randed is more effective than generic. Four-times-a-day is
ore potent than twice-a-day. Larger capsules are stronger
han smaller ones. Interventions, injections, and surgery give
arger effects than pills (17,18).
Pacemaker studies provide striking insight regarding
he placebo response in neurocardiogenic syncope. Com-
aring pacemaker to no pacemaker implantation for
esistant neurocardiogenic syncope, the VPS-I (Vasova-
al Pacemaker Study) was stopped prematurely due to an
pparent marked reduction in syncope from the pace-
aker (19). Considering the possibility that the implant
tself had an important placebo effect, a controlled trial
VPS-II) of a similar population involved pacemaker
mplantation in all patients, but the devices were pro-
rammed off or programmed on in a double-blinded
ashion (15). No significant benefit was derived from
ctive pacing. The rate of syncope was similar to the
acing arm of the VPS-I trial.
Beta-blockers are commonly used and widely believed to
e effective for neurocardiogenic syncope, but a multicenter
ontrolled clinical trial, the POST (Prevention of Syncope
rial), comparing metoprolol to placebo indicated that any
enefit from metoprolol is the same as that benefit derived
rom placebo (20). In retrospect, an ingenious study com-
aring placebo pill (atenolol) to placebo device (pacemaker)
howed that placebo strengths vary by intervention type.
he pacemaker was far superior to a beta-blocker (21). The
uration of the placebo response lasted throughout the
tudy. The POST-II study is now comparing fludrocorti-
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
ICD  implantable
cardioverter-defibrillator
VEGF  vascular
endothelial growth factorone with placebo. cBlinded studies of pacemaker implantation for hypertro-
hic cardiomyopathy show a strong placebo response similar
o the syncope data. Improvement occurred even when an
mplanted pacemaker was disabled in a blinded fashion for
uch patients. A large placebo response overshadowed any
mall or modest effect from active pacing (22–24) with no
onvincing explanatory mechanism identified.
Cardiac resynchronization benefits may be in part due to
lacebo response. The MIRACLE (Multicenter InSync
andomized Clinical Evaluation) trial (25) enrolled patients
ho received a resynchronization device. While the heart
ailure would not be expected to improve, over 6 months,
ven with therapy programmed off in a double-blinded
ashion (a sham device) functional class improved, but not
o the extent as when the device was programmed on. It
emains uncertain how much benefit derived from pacemak-
rs for standard pacing indications (e.g., sinus node dys-
unction or complete atrioventricular block) is due to pla-
ebo effect.
Catheter ablation is extraordinarily effective for many
upraventricular tachycardias and so placebo-controlled tri-
ls appear unnecessary, but questions remain regarding
fficacy of ablation to treat atrial fibrillation (AF). An
pparent benefit of ablation for AF might not be surprising,
iven hope for cure, a reasonable explanatory mechanism,
ractitioner’s hope for success, and the considerable inter-
entional nature of ablation.
Over 2,000 reports have examined AF ablation, but not 1
tudy has had a placebo-controlled design. Many patients
nd clinicians report cure with ablation with excellent
uccesses reported in the literature (26–28), but successes
re not as easy to reproduce as for other types of ablation.
ith aggressive monitoring after ablation, episodes of
symptomatic AF and symptoms unrelated to AF can be
ecorded (29) although these data remain in dispute (30). As
ontemporary treatment for AF is to reduce symptoms with
o other proven benefit, the ethics of performing a con-
rolled clinical trial using a placebo design to provide a
enchmark for safety and efficacy seems advisable.
Placebo appears to influence subjective findings more
han objective measurements, but symptom recognition and
nterpretation is of prime importance for patients with
yncope, heart failure, angina, or any other cardiac condition
hat affects disability or functionality or involves symptom
nterpretation.
agnitude of the Placebo Effect
he magnitude of the placebo effect is difficult to quantitate
ue to its diverse nature (a pill, physician’s advice, surgical
ntervention, patient beliefs, and outcome analyses) and due
o the wide variety of conditions that seem to respond. An
pparent effect can be immeasurable or exceed 80% of a
reatment effect. A placebo can even appear to reduce the
isk of death. For most situations and conditions, placebo
ontributes 30% to 40% to the benefit of an intervention.
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January 30, 2007:415–21 Placebo and Noceboikely, 35% to 50%, if not more, of a response to an
nalgesic or opiate can be attributed to placebo (31–34).
Recombinant human vascular endothelial growth factor
rotein (VEGF) research is instructive regarding how chal-
enging it can be to measure. Vascular endothelial growth
actor protein was expected to improve outcomes in isch-
mic heart disease, but hopes dimmed after the VIVA
Vascular Endothelial Growth Factor in Ischemia for Vas-
ular Angiogenesis) study. Of 178 stable exertional angina
atients randomized to placebo or low- or high-dose VEGF
y intracoronary infusion, angina class and quality of life
mproved significantly within each group indicating a large
lacebo response. By day 120, placebo-treated patients had
educed benefit in all 3 measures similar to those in the
ow-dose VEGF group. High-dose VEGF resulted in
ignificant improvement in angina class (p  0.05) com-
ared with placebo.
These and other (35) data indicate that placebo effects
an be combined with physiological effects and have differ-
nt time-to-effect curves compared with active therapy.
lacebo can be difficult to distinguish from active therapies
epending on expectations, follow-up, study design, and
redefined end points. A study with subjective and contin-
ous end points is more likely to show a placebo effect
ompared with a study with binary and objective end points.
he Nocebo Effect
nocebo effect represents harm perceived by a patient or
dentified by a practitioner arising solely from the appear-
nce that treatment has been delivered. Healthy individuals
ave adverse effects to a blinded sham 15% to 27% of the
ime (36). Adverse events have been reported spontaneously
ith a placebo in 109 double-blind, placebo-controlled
tudies of 1,228 volunteers. Repeat dosing increases nocebo
ffects to 28%; old age is associated with a 26% nocebo
esponse (37,38). If patients are specifically asked about
dverse effects, the percent can rise to 71% (37,39). The
ocebo effect might lead to secondary gain, disability, or
ven death (38,39). Women report nocebo responses to
herapy more than men do, but any impact of practitioner
ender, culture, or other perceived biases on the nocebo
esponse is unclear.
Adverse, often unsubstantiated, drug effects and drug side
ffects, a challenge in practice, may be nothing more than
ocebo. Conventional wisdom that beta-blockers have com-
on adverse effects is not substantiated (40) and may be in
art a nocebo effect amplified by reading package inserts and
arnings or by talking with biased physicians. Of 15 trials,
n over 35,000 patients, beta-blockers were not associated
ith greater risk of depression (6 of 1,000 patients 95%
onfidence interval [CI] 7 to 19) and led only to a small
ssociated risk of fatigue (18 of 1,000 patients; 95% CI 5 to 30)
nd sexual dysfunction (5 of 1,000 patients; 95% CI 2 to 8).
Nocebo can be bothersome non-specific symptoms (41).t can be cause for patients to drop out of clinical trials dhereby biasing results (38). Nocebo effects must be consid-
red when designing clinical trials or treating patients.
ubtle forms of nocebo in clinical practice may be due to
ndisclosed or covert emotional conflicts.
Physician advice, although an indirect form of interven-
ion, can have powerful placebo or, unfortunately, nocebo
ffects. Patients can create their own nocebo effect unwit-
ingly. From the Framingham data, women, with similar
isk factors, were 4 times more likely to die if they believed
hey were prone to heart disease (42). Recent evidence
uggests a link between emotions (such as fear or depres-
ion), cardiomyopathy, and even death. Tako-tsubo cardio-
yopathy, especially prevalent in women, appears related to
n adverse intense emotional stressor (43–45).
Nocebo and placebo responses remain confounders that
xplain much of any therapy’s true benefits and risks. Active
herapies could have additional placebo and/or nocebo
ffects.
thics of Placebo and
ocebo Use in Practice and Research
eliberate placebo use occurs in clinical practice. In 1
eport, 53 of 89 clinicians used placebo as a therapy with 33
f 53 using it at least once a month. Fifteen (28%)
onsidered placebos to be a diagnostic tool. Of the respon-
ents, 48 of 51 (94%) reported placebos to be generally or
ccasionally effective (46). In another report, the authors of
his survey argued that placebo does not always entail
eception and may even be “morally imperative” (47).
With over 3 billion prescriptions written annually, up
0% in slightly over a decade, some drugs are prescribed for
he placebo response. This issue is important since medica-
ions can have adverse effect and these contribute to
100,000 deaths annually from prescription drugs in the
.S. alone (48). Use of standard, accepted therapies, with-
ut adequate evidence base, may rely in part on a placebo
esponse. Such interventions may also cause real adverse
ffects and even death.
Dishonest and deceptive use of a therapy, primarily to
erive covert psychological benefit, but providing no phys-
ological or pharmacological benefit, is fraught with ethical
nd moral dilemmas and presently not considered accept-
ble. An inactive therapy may have no real benefit, be
eutral, or create nocebo effects but exposes patients to
nnecessary risks and may leave underlying medical condi-
ions untreated. Patients who learn of such deceptive prac-
ices will likely lose trust.
Alternatively, if the problem being treated is benign and
ebilitating, if the placebo effect is strong and the risk of
arm is low, if the science does not clearly indicate benefit
f a therapy, or if the condition does not allow for a well
ested therapy, a placebo may be justifiable. This scenario is
ften used under the rubric of doing what is best for the
atients at a time when the data are less than clear. By so
oing, the patient may be buffered from therapies with even
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Placebo and Nocebo January 30, 2007:415–21reater risks. A benign therapy that reduces pain by 80%, for
xample, even if much of the response is placebo, may be
ustifiable as long as the condition is benign and no other
herapy is required.
Research using sham therapies help identify harmful and
seless clinical interventions. They can be crucial and may
e justifiable if no harm comes to the research subject. Trials
omparing 2 purported active therapies using a non-
nferiority or equivalence design may determine feasibility of
therapy, but without a matched placebo, it is not possible
o assess any actual benefit (or harm) derived from the active
reatments. No therapy is not an adequate control as it does
ot match expectations. There are drawbacks and difficulties
ith 3-way study designs involving 1 active therapy, a
atched placebo, and no therapy to assess how much of an
ffect of a therapy is placebo and how much is active
herapy. This type of study design cannot be blinded
dequately.
ham Surgeries
esearch involving sham operations in cardiology help
larify the actual benefit of the therapy. Internal mammary
rtery ligations, once common, are no longer performed
ased on such investigations. Patients with suspected coro-
ary artery disease who had angina underwent a sham
rocedure (skin incision) or an internal mammary ligation
an ineffective surgery). Both groups improved. Even
readmill-induced ST-segment depression improved with
lacebo (49). These data were reproduced (50).
Coronary artery bypass graft surgery, stent implantation,
nd AF ablation have not been tested against a matched
ham control to show the actual benefit derived from these
rocedures, but such a control may be unacceptable, impos-
ible, unethical, and impractical. One randomized con-
rolled trial that will never be completed is comparison of a
ham implantable cardioverter-defibrillator (ICD) against
n actual ICD to evaluate risk reduction of mortality in a
igh-risk population. The SCD-HeFT (Sudden Cardiac
eath Heart Failure Trial) did evaluate a placebo pill in a
-arm study design (51). The placebo pill may be a good
atch for amiodarone, but hardly for the ICD. The benefit
f an ICD cannot be calculated with certainty without a
atched placebo. Nevertheless, such a comparison is out of
ine with clinical equipoise.
Neurosurgeons have performed, carefully controlled,
nd matched placebo surgical evaluations, so it should be
ossible for cardiologists and cardiovascular surgeons to
o the same. One such study involved Parkinson’s disease
atients randomized to embryonic fetal cell brain im-
lants or sham surgery (holes drilled in the head) (52).
oth groups improved similarly regarding the primary
utcome of disease severity eliminating this as a viable
reatment option. sechanisms of Placebo Effects
ack of consensus regarding what constitutes the placebo
ffect may explain in part why some data indicate a real
esponse to placebo and other data do not. Responses that
hape the placebo effect are likely an actual physiological
esponse combined with natural history of and spontaneous
uctuations in the disease state, spontaneous remission,
atient beliefs and expectations, observer enthusiasm and
xpectations, random variability, regression to the mean,
nd other obscure issues. Statistical anomalies can contrib-
te to the placebo effect. Sample size is important. The
ikelihood of a placebo effect is greater in smaller data sets.
ime of follow-up is important. Shorter follow-up increases
he likelihood of a placebo effect that may fade with time.
Part of the response is due to expectations, culture,
ender, and race of the subject and of the experimenter.
ome placebo benefit may be hard-wired behavior with a
enetic basis. Unwittingly (or by poor study design), the
ractitioner may be the one experiencing the greatest benefit
f the therapy. Placebos may even work if a patient is
nowingly taking one (53).
europhysiologic effects. Placebo can change sensitivity
n perceptions related to neurocognitive pathway alterations.
lacebo can release endorphin (54,55). This may initiate a
ardiovascular response (56). For pain, disinhibiting nitric
xide signaling and opioid mu receptor activation could
ffects nigral and tegmental dopamine output by gamma
minobutyric acid neurons, ultimately affecting mesolimbic
nd mesocortical reward and motivation circuitries (57).
ositron emission tomography brain scanning provides
vidence of endogenous neurotransmitter dopamine release
n Parkinson’s disease patients in response to placebo (58).
lectroencephalogram brain mapping suggests that a pla-
ebo response may have different mechanisms of action than
n active drug even though the response is similar (59).
lacebo responses could complement an active drug (or
ork against it).
onditioning effects. Conditioning can elicit a placebo
esponse. Rats drinking saccharin-flavored water with cy-
lophosphamide had immunosuppression. Ten days later,
fter recovery, one-half the rats received saccharin; the other
alf received nothing. Saccharin lowered antibody titers
ersus control 8 days after antigenic stimulation (60).
imilarly, patients may be “hard wired” to develop a condi-
ioned placebo response. Conditioning may be more impor-
ant than expectation (61).
xpectation effects. An expectation of, or hope for,
enefit from a treatment can explain placebo effects. Low
xpectations will reduce or eliminate the placebo effect
61). Expectation has neurophysiological impact as mea-
ured by a functional magnetic resonance imaging (62)
nd can affect outcomes based on patient and practitioner
nterpretations (63). Several types of expectation re-
ponses exist (Table 1).
i
u
o
s
T
a
T
“
t
t
c
b
d
s
p
f
u
i
s
n
w
t
a
t
s
9
p
a
T
r
b
i
m
m
o
m
w
P
A
C
l
T
t
O
p
c
c
2
m
s
t
i
m
w
B
t
p
a
5
p
b
o
i
w
I
P
d
e
l
a
a
c
t
l
a
F
s
a
e
r
m
o
m
r
s
b
DE
419JACC Vol. 49, No. 4, 2007 Olshansky
January 30, 2007:415–21 Placebo and NoceboExpectation in clinical trials can affect a placebo response
f the participant has past clinical trial experience, has
ndergone medication changes, has had procedures, has fear
f being a placebo responder, gets input from or has trust in
tudy or non-study doctors, or has a fear of side-effects (64).
his is most patients. Paying a high price for a therapy may
ffect expectations.
he meaning response: a form of expectation. The
meaning response” is a plausible, understandable, explana-
ion of an illness (even if a manufactured concept) and/or
reatment. Interpretation of the meaning and impact of a
ondition affects patient responses. “The chest pain is
enign and due to a problem in the esophagus” is completely
ifferent than: “The chest pain is due to blocked arteries
upplying blood to your heart. You will probably die soon.”
Sox et al. (65) found that performing a series of tests in
atients with non-specific chest pain could reduce disability
rom 45% to 20% even if the tests were negative or
nnecessary. Simply performing tests in patients with atyp-
cal chest pain can have a beneficial effect even though
tructural heart disease is not present. While these results do
ot necessarily represent a modern population of patients
ith chest discomfort and there may be issues of study rigor,
he point is clear—evaluation can change the perceptions
nd expectations regarding outcomes.
As part of the meaning response, apparent rational
herapy can influence outcomes even if the therapy is a
ham. Consider a patient with a coronary artery that is
9% blocked. It makes sense, and has meaning to the
atient and to the physician, that opening the artery to
ugment coronary blood flow will improve the outcome.
his line of reasoning makes sense whether or not it
eally is true and whether the therapy is effective or not,
ut it offers a placebo effect. Transmyocardial revascular-
zation may provide placebo response due to its proposed
echanism of action. Vascular endothelial growth factor
ay have had benefit by this same mechanism overshad-
wing other possible benefits. Angioplasty, stent place-
ent coronary artery bypass graft surgery, and AF may
efinitions of Some Expectationffects Behind the Plac bo Response
Table 1 Definitions of Some ExpectationEffects Behind the Placebo Response
Hawthorne effect Subjects respond to knowledge of being evaluated and
observed
Jastrow effect Subjects respond to explicit expectation about outcome
Pygmalion effect Evaluators expect therapeutic benefit, so they see it
John Henry effect Control subjects attempt to emulate expected outcomes
Halo effect Subjects respond to treatment novelty (i.e., new
technology)
Experimenter
effect
Evaluators consciously (or not) interpreted outcomes
differently
Socialization effect Others reporting feigned (apparent) benefit influence
outcomes
Value effect Costs influence expected outcomesork partially by this mechanism. natient Compliance and
dherence: Indicators of Expectation?
ompliance and adherence to placebo affects outcomes or at
east differentiates therapy responders from non-responders.
he Coronary Drug Project enrolled about 5,000 men in
he 1960s. High-risk men received clofibrate or placebo.
ver 5 years, mortality was the same in both groups, but
atient outcomes varied by compliance. For those 80%
ompliant to placebo, the mortality was 15%, similar to
lofibrate, but for those compliant 80%, the mortality was
8% (similar to clofibrate) (p  1016) making this the
ost statistically significant study in cardiology to date. No
pecific parameters predicted compliance (66). At the time,
he authors stated that, unless this response was understood,
t could be very difficult to understand any study results or
ake sense of clinical trials.
This observation has been reproduced. The same results
ere seen after myocardial infarction (67). In the Beta-
locker Heart Attack Trial, among 2,175 participants,
hose who did not adhere well to treatment (taking75% of
rescribed medication) were 2.6 times more likely than good
dherers to die within a year of follow-up (95% CI 1.2 to
.6). Poor adherers had an increased risk of death taking
lacebo (odds ratio 2.5), and this risk was not accounted for
y severity of disease, sociodemographic features, smoking,
r psychological characteristics. The same finding was seen
n patients with congestive heart failure patients (68) and
ith hypertension (69).
s Placebo Powerful or Powerless?
erhaps the greatest single observable consistent and repro-
ucible effect seen over time in medicine is the placebo
ffect. If it is simply a fake, then perhaps all of medicine is
argely a sham. This hypothesis is untenable.
Taking the tact that placebo is powerless, Hrobjartsson
nd Gotzsche (10) sought to prove this based on a meta-
nalysis of 130 trials involving 3,795 patients. The placebo
ompared with no therapy had no effect in the conditions
ested. The analysis showed no difference for pharmaco-
ogic, physical, or psychological placebos leading some to
bandon the idea that a placebo has an effect. Not all agree.
or specific conditions, re-analysis of the same data has
hown different results (11) perhaps revealing biases. That
side, much of what is considered placebo may be due to
xpectation effects, built in biases in patient assessment, and
eporting and conditioning responses.
The difference between powerful and powerless placebo
ay relate to what the placebo is considered to be. The lack
f a singular criterion for placebo definition across studies
ight underlie the core of the debate. The issue is often
elated to how a placebo is used and/or how the results of a
tudy are observed and evaluated. Apparent and actual
enefit can be difficult to separate. The common denomi-
ator, the core of the placebo response, is not the therapy
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Placebo and Nocebo January 30, 2007:415–21ut the dynamic between patient and physician. This
ynamic cannot be factored out in studies performed and
hose analyzed by Hrobjartsson and Gotzsche (10). Other
ata point to this interaction as being crucial (70).
hysicians—the unwitting contributor to the placebo
esponse. Placebo responses are seen because they are
xpected or predicted. The doctor can enhance the placebo
esponse and be a knowing or unwitting contributor to it. In
double-blinded trial for pain, 1 group received a narcotic
nalgesic, narcotic antagonist, or placebo and the other
eceived a narcotic antagonist or placebo. Doctors who
new which group was which gave the therapy. The first
roup had a better outcome (71).
Concealed random allocation (to counterbalance experi-
enter and subject expectancies) may offset these issues.
elective reporting, focusing only on positive outcomes, can
e misleading but may represent part of the placebo effect.
valuating specific clinical conditions rather than looking at
he group as a whole may be another contributor. All these
ssues must be considered in order to design a robust
ouble-blinded placebo-controlled clinical trial in which
xpectancies are eliminated.
uture Research
standardized (narrow) definition of placebo will help
etter identify how placebos work. Until placebo is better
efined and understood, the placebo effect will remain a real
henomenon. More carefully designed studies that identify
nd compare placebos may help clarify the issues. Such
tudies are underway.
onclusions
lacebo and nocebo effects are common in practice. An
nderstanding of these effects is vital to evaluate outcomes
airly in research. Placebo and nocebo ultimately involve
alutary and deleterious interactions (and their interpreta-
ion) between patient and doctor. Placebo is time-tested and
s an intricate part of successful medical care.
A cold, uncaring, disinterested and emotionless physician
ill encourage a nocebo response. In contrast, a caring,
mpathetic, physician fosters trust, strengthens beneficent
atient expectations, and elicits a strong placebo response. A
ompassionate, hands-on approach may be more valuable
han any single medical therapy. Generally undervalued,
ften unrecognized, placebo helps define our profession.
he doctor, the nurse, the healthcare provider are the most
aluable resources for healing patients.
A 2005 U.S. News and World Report cover stated: “Who
eeds Doctors? Your next doctor may not be an MD and
ou may be better off.” Have we finally come this far, where
he human touch of the physician can be replaced by
ealthcare reduced to guidelines, tests, algorithms, proce-
ures, and drugs?
It is unlikely that patients would accept depersonalized
edicine no matter how far technology progresses and noatter how hard the benefits of the doctor-patient relation-
hip are sterilized, dissected, and disregarded. The personal
ole doctors have in patients’ lives has made the medical
rofession one of the most respected and time-honored
rofessions. If the placebo response as part of the doctor-
atient dynamic is alive, patients will be happier and
ealthier. Without placebos, the doctor’s role will deterio-
ate or disappear, and patients will suffer. Placebos work!
eprint requests and correspondence: Dr. Brian Olshansky,
ardiac Electrophysiology, University of Iowa Hospitals, 4426a
CP, 200 Hawkins Drive, Iowa City, Iowa 52242. E-mail:
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